Natco Pharma Share Price Drops After USFDA Issues 7 Observations

We saw Natco Pharma’s share price slide after the U.S. Food and Drug Administration (USFDA) raised seven observations at its Hyderabad facility. This isn’t just a small hiccup; regulatory scrutiny from the USFDA often sets off alarm bells for investors. Natco has responded with confidence, saying it will fix the issues. But the market’s reaction shows that investors are taking this very seriously.